Chapter 9 Previous line

Previous line identifier is [pl]

9.1 Definition

Instrument previous line refers to any anticancer treatment received, either for a prior cancer or for the current cancer, before the current line.

The current line is the most recently administered one that contains immune checkpoint inhibitors. It can be ongoing at the time of index cardiotoxicity, or may have been interrupted.

Non-ICI anticancer treatments are grouped by pharmacological class and all are attributed a 4-character abbreviation (e.g. cl_anth_ambi refers to a current line use of anthracycline ambirubicin). For drugs out of the list, there is an “other” section, with abbreviation othr, followed by a freetext variable.

9.2 Abbreviations

Abbreviation(s)	Feature
	Immune checkpoint inhibitors
atez avel cemi durv nivo ipil pemb trem	Standardized 4-character abbreviations of immune checkpoint inhibitors Atezolizumab, avelumab, cemiplimab, durvalumab, nivolumab, ipilimumab, pembrolizumab, tremelimumab
pd1 pdl1 ctla4	When drug name is not know, standardized abbreviations related to ICI class. Anti-PD1, anti-PD-L1, anti-CTLA4 Also pd1_other, pdl1_other, and ctla4_other to refer to an ICI from a class that is not in the aforementioned list (e.g. a new anti-PD1)
	Other anticancer treatments
anth	Anthracyclines
alky	Alkylating agents
anme	Antimetabolites
plal	Plant Alkaloïds
atbo	Antitumor antibiotics
topo	Topoisomerase inhibitors
her2	Anti-HER2 therapies
vegf	Vascular Endothelial Growth Factor inhibitors
bcra	BCR-ABL inhibitors
btki	Bruton Tyrosin Kinase inhibitors
rafm	RAF or MEK inhibitors
egfr	Endothelial Growth Factor Receptor inhibitors
prot	Proteasom inhibitors
cell	Cell Therapies (mostly CAR-T Cells)
immd	Immunomodulators, other than Immune Checkpoint Inhibitors and Cell Therapies